▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #319 by analyst upside · 2026-09-27
IRIX
IRIDEX Corporation
Healthcare · Market Cap $11M · P/E 0x
ANALYST PRICE TARGET
+340.0%
implied upside to consensus target
Current Price $0.62
Consensus Target $2.75
Bull Target $2.75
Bear Target $2.75
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $0.61
52-Week High $1.65
YTD Return -46.2%
FUNDAMENTALS
Market Cap $11M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.20
PEG Ratio 0.94
Dividend Yield N/A
Revenue (TTM) $52M
Profit Margin -6.9%
52-WEEK RANGE
52-Week Low $0.61
52-Week High $1.65
Current Price $0.62
Bear Target $2.75
Bull Target $2.75
● Now $0.62 ● Target $2.75
TRADING DATA
Avg Volume 69K
YTD Return -46.2%
Analyst Count 1
Consensus Buy
Upside to Target +340.0%
Last Updated 2026-09-27

ANALYST SUMMARY

IRIDEX Corporation (IRIX) is currently trading at $0.62 with a Wall Street consensus price target of $2.75, implying potential upside of 340.0% over the next 12 months. 1 analysts currently cover IRIX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $2.75, while the most cautious has a target of $2.75.

IRIX operates in the Healthcare sector with a market capitalisation of $11M. The stock is down 46.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.61 – $1.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →